Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials

Roy Freeman,1 Birol Emir,2 Bruce Parsons2 1Autonomic and Peripheral Nerve Laboratory, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; 2Pfizer Inc, New York, NY, USABackground: Greater understanding of factors associated with the high placebo-response rates noted in re...

Full description

Bibliographic Details
Main Authors: Freeman R, Emir B, Parsons B
Format: Article
Language:English
Published: Dove Medical Press 2015-06-01
Series:Journal of Pain Research
Online Access:http://www.dovepress.com/predictors-of-placebo-response-in-peripheral-neuropathic-pain-insights-peer-reviewed-article-JPR
_version_ 1818426665157525504
author Freeman R
Emir B
Parsons B
author_facet Freeman R
Emir B
Parsons B
author_sort Freeman R
collection DOAJ
description Roy Freeman,1 Birol Emir,2 Bruce Parsons2 1Autonomic and Peripheral Nerve Laboratory, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; 2Pfizer Inc, New York, NY, USABackground: Greater understanding of factors associated with the high placebo-response rates noted in recent neuropathic pain trials may improve trial design. This study investigated placebo response and its predictors in pregabalin trials in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia.Patients and methods: Individual patient data from 16 randomized, placebo-controlled, double-blind trials of pregabalin in 3,053 patients with DPN and 1,460 patients with postherpetic neuralgia were pooled (by condition and all together) in order to investigate the placebo response and its predictors. Univariate and multivariate analyses were performed across all 16 trials to identify predictors of change in pain score in patients. Trials with a >2-point mean reduction in pain score at endpoint with placebo were designated high placebo response and were compared with low placebo-response trials (those with a ≤2-point mean reduction) with respect to patient and study characteristics.Results: Three high placebo-response studies were identified, with all in DPN patients and all conducted postapproval of pregabalin. Younger age, higher mean baseline pain score, longer study duration, higher ratio of patients on active treatment to placebo, and study conducted postapproval were all significantly associated with a higher placebo response (P<0.05). There was a trend towards an increased placebo response in all studies over time without any corresponding change in the response to pregabalin.Conclusion: Consideration of the factors identified here as contributing to a higher placebo response could help improve the sensitivity and accuracy of clinical trials in patients with neuropathic pain.Keywords: diabetic peripheral neuropathy, postherpetic neuralgia
first_indexed 2024-12-14T14:33:26Z
format Article
id doaj.art-e85a8f1b2fbd4e60827418d07c241e04
institution Directory Open Access Journal
issn 1178-7090
language English
last_indexed 2024-12-14T14:33:26Z
publishDate 2015-06-01
publisher Dove Medical Press
record_format Article
series Journal of Pain Research
spelling doaj.art-e85a8f1b2fbd4e60827418d07c241e042022-12-21T22:57:44ZengDove Medical PressJournal of Pain Research1178-70902015-06-012015default25726821956Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trialsFreeman REmir BParsons BRoy Freeman,1 Birol Emir,2 Bruce Parsons2 1Autonomic and Peripheral Nerve Laboratory, Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA; 2Pfizer Inc, New York, NY, USABackground: Greater understanding of factors associated with the high placebo-response rates noted in recent neuropathic pain trials may improve trial design. This study investigated placebo response and its predictors in pregabalin trials in patients with diabetic peripheral neuropathy (DPN) or postherpetic neuralgia.Patients and methods: Individual patient data from 16 randomized, placebo-controlled, double-blind trials of pregabalin in 3,053 patients with DPN and 1,460 patients with postherpetic neuralgia were pooled (by condition and all together) in order to investigate the placebo response and its predictors. Univariate and multivariate analyses were performed across all 16 trials to identify predictors of change in pain score in patients. Trials with a >2-point mean reduction in pain score at endpoint with placebo were designated high placebo response and were compared with low placebo-response trials (those with a ≤2-point mean reduction) with respect to patient and study characteristics.Results: Three high placebo-response studies were identified, with all in DPN patients and all conducted postapproval of pregabalin. Younger age, higher mean baseline pain score, longer study duration, higher ratio of patients on active treatment to placebo, and study conducted postapproval were all significantly associated with a higher placebo response (P<0.05). There was a trend towards an increased placebo response in all studies over time without any corresponding change in the response to pregabalin.Conclusion: Consideration of the factors identified here as contributing to a higher placebo response could help improve the sensitivity and accuracy of clinical trials in patients with neuropathic pain.Keywords: diabetic peripheral neuropathy, postherpetic neuralgiahttp://www.dovepress.com/predictors-of-placebo-response-in-peripheral-neuropathic-pain-insights-peer-reviewed-article-JPR
spellingShingle Freeman R
Emir B
Parsons B
Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
Journal of Pain Research
title Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
title_full Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
title_fullStr Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
title_full_unstemmed Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
title_short Predictors of placebo response in peripheral neuropathic pain: insights from pregabalin clinical trials
title_sort predictors of placebo response in peripheral neuropathic pain insights from pregabalin clinical trials
url http://www.dovepress.com/predictors-of-placebo-response-in-peripheral-neuropathic-pain-insights-peer-reviewed-article-JPR
work_keys_str_mv AT freemanr predictorsofplaceboresponseinperipheralneuropathicpaininsightsfrompregabalinclinicaltrials
AT emirb predictorsofplaceboresponseinperipheralneuropathicpaininsightsfrompregabalinclinicaltrials
AT parsonsb predictorsofplaceboresponseinperipheralneuropathicpaininsightsfrompregabalinclinicaltrials